KPV's Category 2 Withdrawal: What It Means and What It Doesn't
KPV is a three-amino-acid peptide, lysine-proline-valine, that forms the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has circulated in compounding and research contexts as an anti-inflammatory agent, mostly discussed for gut, skin, and systemic inflammatory applications covered elsewhere in this cluster (see KPV for IBD and ulcerative colitis and KPV for eczema and psoriasis). None of that discussion changes the regulatory question this page answers: where does KPV actually stand with FDA, right now.
What did "Category 2" mean, and why does the withdrawal matter?
FDA maintains a list of bulk drug substances nominated for use in compounding under section 503A, and sorts nominations into categories based on safety signal review. Category 2 substances are those FDA has identified as raising significant safety risks for compounding use, a designation that functions as a caution flag, not a ban in itself. KPV was nominated into this review process, but the nomination was subsequently withdrawn by the parties who submitted it. According to FDA's Category 2 bulk substances page, KPV is no longer listed in Category 2 (content current as of 04/22/2026): FDA Certain Bulk Drug Substances page.
Withdrawal here means the safety-risk review process for KPV under that specific nomination ended without FDA completing or finalizing a Category 2 placement. It does not mean FDA evaluated KPV and cleared it. It does not mean the underlying safety question was resolved in KPV's favor. A withdrawn nomination is closer to a paused case file than a verdict.
Does withdrawal mean KPV is approved or legal to compound?
No. This is the point worth repeating because it is the most common misreading. FDA maintains a separate list, the 503A bulks list, of substances confirmed appropriate for use in compounding under section 503A. KPV is not on that list. FDA's framework page for 503A bulk substances lays out how substances get added to or excluded from that list, and KPV's absence from it as of this writing means compounders have no confirmed FDA pathway for it: FDA 503A Bulk Drug Substances framework.
KPV also has no FDA-approved drug application of its own. It is not a marketed, approved medication for any indication. There is no enforcement discretion policy in effect that specifically covers compounding KPV. Put plainly: a nomination being withdrawn removed one specific regulatory flag, but it did not create approval, did not create legality to compound, and did not place KPV on any confirmed-substances list.
What happened at the July 2026 advisory committee meeting, and does that change anything?
On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) met and voted on whether to recommend adding KPV to the 503A bulks list. The vote was 8 yes, 6 no, 1 abstain, in favor of recommending addition. That meeting is documented on FDA's advisory committee calendar: July 23-24, 2026 PCAC meeting page.
This vote is advisory only. PCAC recommends; it does not add substances to the list itself, and FDA is not bound to follow an advisory committee's recommendation. HHS and FDA still need to take formal action, through rulemaking or listing procedures, before KPV could actually appear on the 503A bulks list. As of September 2026, that action has not occurred. The close 8-6 vote also signals real disagreement among the committee members reviewing the same evidence, not a consensus recommendation.
So the sequence, precisely, is: nomination into Category 2 review, withdrawal of that nomination, and separately, an advisory committee vote recommending a different, affirmative listing action that has not yet been finalized. These are three distinct regulatory events. None of them, individually or together, constitutes FDA approval of KPV or confirmed legal status for compounding it.
What does the clinical evidence actually cover, separate from the regulatory question?
It is worth being clear that the regulatory uncertainty above is independent of what the biological literature shows, and the literature itself has real limits. Most KPV research is preclinical: cell-culture work and animal models, not controlled human trials. Early work described alpha-MSH-derived peptides, including KPV-containing sequences, having antimicrobial and antifungal activity in vitro (Journal of Leukocyte Biology, 2000; Journal of Peptide Research, 2005). Immune-modulating and anti-inflammatory effects have been studied across several models, including endotoxin-induced inflammation in animals (Journal of Surgical Research, 2006) and broader reviews of alpha-MSH-related peptides as an anti-inflammatory drug class (Annals of the Rheumatic Diseases, 2007; Endocrine Reviews, 2008).
The gut-inflammation research is the most developed strand and largely mouse-model based: KPV taken up via the intestinal PepT1 transporter reduced inflammation in murine colitis models (Gastroenterology, 2008; Inflammatory Bowel Diseases, 2008), with later work extending this to colitis-associated cancer models (Cellular and Molecular Gastroenterology and Hepatology, 2016) and nanoparticle-delivery formulations aimed at improving oral targeting to the colon (Molecular Therapy, 2017). Skin-related work includes a tripeptide derivative's effects on sebocyte cytokine signaling (Journal of Immunology, 2010) and a broader review of melanocortin peptides in wound healing (Experimental Dermatology, 2019). None of this constitutes human clinical trial evidence establishing safety or efficacy for a specific indication, and none of it changes KPV's regulatory status. Readers evaluating specific clinical claims should see the dedicated pages on IBD and ulcerative colitis evidence and systemic use questions, which weigh this same preclinical literature against clinical relevance.
A quick decision framework for reading regulatory status claims
Because "withdrawn," "recommended," and "approved" get conflated constantly in peptide marketing, it helps to have a simple test before trusting any claim about KPV's legal status.
KPV regulatory claim verification checklist
| Claim you encounter | What to check | Current answer (Sept 2026) |
|---|---|---|
| "KPV was cleared by FDA" | Is there an approved drug application or monograph? | No approved application exists |
| "KPV is off Category 2, so it's fine to compound" | Is KPV on the 503A bulks list specifically? | Not on that list |
| "FDA added KPV to the compounding list" | Was this FDA action or advisory committee recommendation? | Advisory-only PCAC vote, not final FDA action |
| "The withdrawal proves it's safe" | Does a withdrawn nomination equal a safety finding? | No, withdrawal ends that review without a safety determination |
| "It's legal because the committee voted yes" | Is a 8-6 advisory vote binding? | No, HHS/FDA action still required |
If a source cannot answer the middle column with a specific FDA document or list, treat the claim as unverified.
What should a patient or clinician take from this?
The honest summary is narrower than most marketing around KPV suggests. The Category 2 withdrawal removed one specific safety-review flag but created no approval and no confirmed compounding pathway. The July 2026 advisory vote shows regulatory movement and real, divided expert opinion, but it is a recommendation, not a rule change, and KPV remains off the 503A bulks list as of this writing. Anyone considering a compounded KPV product should treat its regulatory status as unresolved, not settled in either direction, and should discuss that uncertainty explicitly with a prescriber rather than relying on marketing language about "FDA review" or "advisory approval." For dosing and formulation-specific questions once regulatory status is understood, see KPV dosing considerations and the comparison with topical steroids for context on alternatives with established approval pathways.
Material uncertainty remains on three fronts: whether FDA will act on the PCAC recommendation and on what timeline, whether any future listing would include conditions or restrictions, and whether the underlying human clinical evidence will ever catch up to the preclinical signal. None of these are resolved by the events described on this page.